Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 9 - Medicinal preparations characterised by special physical form
Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
09/2005
09/01/2005US20050192255 Sustained release composition for cardio-, cerebro- and peripheral vascular diseases of a Vitamin D receptor activators, e.g., paricalcitol, calcitriol, doxercalciferol, and optionally an angiotensin converting enzyme inhibitor, an angiotensin II receptor I blocker, an aldosterone blocker; no side effect
09/01/2005US20050192236 A substantially crystalline clindamycin free base of three polymorphic/pseudopolymorphic forms; water insoluble so useful for sustained release formulations; storage stability; powder x-ray diffraction; differential scanning calorimetry; bactericides
09/01/2005US20050192235 Compositions and methods for treating or preventing diseases of body passageways
09/01/2005US20050192234 Crystal forms of azithromycin
09/01/2005US20050192233 Composition of matter comprising a lanolin free absorption base and method of making
09/01/2005US20050192222 Pharmaceutical preparations and medicine capable of generating and/or containing thrombin
09/01/2005US20050192217 Utilization of lipopeptides or lipoproteins in wound treatment and infection prophylaxis
09/01/2005US20050192216 Freeze- or vacuum-dried native Factor VIII composition containing trehalose as a stabilizer and no albumin; may be reconstituted with water or brine for administration to a hemophilic patient by injection; stable at up to 60 degrees C.
09/01/2005US20050192214 Cyclosporine analogue mixtures and their use as immunomodulating agents
09/01/2005US20050192213 Echinocandin pharmaceutical formulations containing micelle-forming surfactants
09/01/2005US20050191649 Identifying mutation in oligoadenylate synthetase gene (OAS1); identifying modulators for prevention and treatment of cell proliferative, nervous system and diabetic disorders
09/01/2005US20050191491 Polymer coating/encapsulation of nanoparticles using a supercritical antisolvent process
09/01/2005US20050191374 Soluble composition containing sporopollenin and the use thereof
09/01/2005US20050191373 Agent for the prevention and/or treatment of septicemia
09/01/2005US20050191367 Administering a therapeutically effective amount of arsenic compounds, optionally along with other non-arsenic therapeutic agents, to a mammal for treating solid tumors
09/01/2005US20050191366 Process for treating contact dermatitis
09/01/2005US20050191362 Method of preparing microcapsules encapsulating a phase transition material
09/01/2005US20050191361 High-velocity particle injection techniques for transdermal or transmucosal delivery of a pharmacologically active agent using a hydrogel
09/01/2005US20050191360 Dry powder inhaled PTH formulations; Dipalmitoylphosphatidylcholine and sodium citrate; Parathyroid hormone; maintainence of parathyroid hormone chemical stability
09/01/2005US20050191359 Hydrophilic dispersion; a macrolide antibiotic, donepezil hydrochloride, an azole compound or a taxane; and an amphiphilic polymer which wraps the active compound in a non-crystalline manner to form a nano-sized molecular entity
09/01/2005US20050191358 Microparticles with adsorbed polynucleotide-containing species
09/01/2005US20050191357 Method of manufacturing chemical-containing composite particles
09/01/2005US20050191356 Porous and non-porous matrices based on chitosan and hydroxy carboxylic acids
09/01/2005US20050191353 Process for manufacture of stable oral multiple unit pharmaceutical composition containing benzimidazoles
09/01/2005US20050191352 Cutting the controlled release pharmaceutical extrudate as it emerges from the melt extruder under pressure and still molten or softened from the orifices of the die-plate
09/01/2005US20050191351 A once-daily dosage will give steady state blood levels of trospium of a minimum of about 0.5 ng/ml and a maximum of about 6.0 ng/ml.
09/01/2005US20050191350 Tablet prepared by wet granulation of povidone as a binder
09/01/2005US20050191349 Sustained release; fast dissolving; for treatment of Alzheimer's disease
09/01/2005US20050191348 Neurodegenerative disease, dementia, affective or mood disorder, drug use and dependence, memory loss disorder, acute neurological traumatic disorder or neurotrauma
09/01/2005US20050191347 Pharmaceutical formulations
09/01/2005US20050191346 Two separate chambers, a dividing wall of two layers of material adhered together
09/01/2005US20050191345 Temperature-sensitive liposomal formulation
09/01/2005US20050191344 Imidazolyl Derivatized Distearoylphosphatidylethanolamine for delivery of a polyanionic compound, such as a nucleic acid, polynucleotide, a polysaccharide or a negatively charged protein to a cell
09/01/2005US20050191343 Micellar systems useful for delivery of lipophilic or hydrophobic compounds
09/01/2005US20050191342 Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity
09/01/2005US20050191341 Encapsulated aqueous solution; stress, tension headaches, attention deficit disorder hyperactivity, claustrophobia, hyperactivity, and anxiety
09/01/2005US20050191340 If attempting to dissolve the buprenorphine from the patch, the antagonist also has to be dissolved; abuse is difficult to impossible
09/01/2005US20050191339 Bandage of a flexible cover layer and a water-insoluble, adhesive styrene block copolymer for the controlled delivery of a pharmaceutically active ingredient to the skin
09/01/2005US20050191338 Gelling agent and a solvent, with a dissolved or suspended drug suitable for transdermal delivery and a skin permeation enhancer
09/01/2005US20050191337 Adhesive polymer matrix with magnetic particles for contact with the skin, with an active substance; cosmetic or dermatological treatment
09/01/2005US20050191336 Dissolving thin film xanthone supplement
09/01/2005US20050191334 Sustained release device for implantation in the vitreal chamber or the posterior segment of the eye releasing a corticosteroid for an extended period of time
09/01/2005US20050191325 Cushioning wax beads for making solid shaped articles
09/01/2005US20050191324 Improving taste and solubility of such as ritonavir and/or lopinavir; sweetening and flavoring
09/01/2005US20050191323 Pharmaceutical formulations comprising paclitaxel, derivatives and pharmaceutically acceptable salts thereof
09/01/2005US20050191322 Isotonic solutions containing lens epithelial proliferation inhibitors; ophthalmic surgery lens transplanting
09/01/2005US20050191319 Microparticles with adsorbent surfaces, methods of making same, and uses thereof
09/01/2005US20050191314 vaccine comprosing a mixture of A beta oligomers capable of generating an immune response; prophylaxis and treatment of Alzheimer's disease
09/01/2005US20050191310 Novel compositions of saponin adjuvants and excipients
09/01/2005US20050191308 Adjuvant combinations for immunization composition and vaccines
09/01/2005US20050191292 of reversing cognitive decline by administering a humanized antibody that binds to A beta; particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease or Down's syndrome.
09/01/2005US20050191288 Administering to patient before or simultaneously with surgery at least one heparinase enzyme, wherein heparinase enzyme decreases localized inflammatory response in the tissue of the patient
09/01/2005US20050191277 Methods of treating various cancers using melanoma differentiation associated protein-7
09/01/2005US20050191275 Method for short-term and long-term drug dosimetry
09/01/2005US20050191270 Anti-infectious hydrogel compositions
09/01/2005US20050191267 Mulberry extract; whitening effects for darkened skin through antityrosinase activity, antioxidant and anti-inflammatory properties
09/01/2005US20050191260 Hair growth formulation
09/01/2005US20050191246 Powders comprising low molecular dextran and methods of producing those powders
09/01/2005US20050191245 Nasal administration of calcium channel, blockers for treatment of hypertension and other cardiovascular disorders
09/01/2005US20050191244 Abuse-resistant pharmaceutical dosage form
09/01/2005US20050189291 Porous, molecularly imprinted polymer and a process for the preparation thereof
09/01/2005DE10393319T5 Nicht-Gelatine-Filme mit verbesserten Sperreigenschaften Non-gelatin films having improved barrier properties
09/01/2005DE102004007473A1 Mischung, umfassend ein Tensid und ein Cotensid Mixture comprising a surfactant and a cosurfactant
09/01/2005DE102004005009A1 Verzögert freisetzende pharmazeutische Zusammensetzung von Indapamid The sustained release pharmaceutical composition of indapamide
09/01/2005CA2816904A1 Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof
09/01/2005CA2788707A1 Compositions and methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells
09/01/2005CA2558682A1 Targeted delivery of rna interference molecules for the treatment of ige-mediated disorders
09/01/2005CA2557524A1 Biocompatible polymeric delivery systems for sustained release of quinazolinones
09/01/2005CA2556690A1 New complexes
09/01/2005CA2556450A1 Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof
09/01/2005CA2556248A1 Compositions and methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells
09/01/2005CA2556229A1 System immune activation method using non cpg nucleic acids
09/01/2005CA2556216A1 Combination of a nmda receptor antagonist and an anti-depressive drug mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions
09/01/2005CA2556212A1 Implantable drug delivery device including wire filaments
09/01/2005CA2555841A1 Interleukin-13 antagonist powders, spray-dried particles, and methods
09/01/2005CA2555826A1 Compositions and methods for enhanced mucosal delivery of y2 receptor-binding peptides and methods for treating and preventing obesity
09/01/2005CA2555774A1 Compression-coated tablets and manufacture thereof
09/01/2005CA2555423A1 Particulates
09/01/2005CA2555406A1 Improved therapy using a combination of raloxifene and alendronate
09/01/2005CA2554695A1 Solid formulations of ospemifene
09/01/2005CA2552903A1 Pharmaceutical compositions based on anticholinergics and pegsunercept
09/01/2005CA2552902A1 Multilayer tablet
09/01/2005CA2545591A1 Artificial synapse chip
08/2005
08/31/2005EP1568379A1 Medicinal preparation having chemotherapeutic encapsulated therein
08/31/2005EP1568370A1 Topical antibacterial formulations
08/31/2005EP1568366A1 Antifungal and/or antimycotic external preparation for nail comprising neticonazole
08/31/2005EP1568365A1 Warm poultice
08/31/2005EP1568363A2 Compositions and methods for improving integrity of compromised body passageways and cavities
08/31/2005EP1568362A1 Divisible tablet
08/31/2005EP1568361A2 Sustained-release pharmaceutical composition containing tamsulosin
08/31/2005EP1568360A1 Liposome
08/31/2005EP1568359A1 Drug delivery system using subconjunctival depot
08/31/2005EP1568346A1 Process for producing edible orally administered agent of laminate film form and compression bonding apparatus
08/31/2005EP1567513A2 High enantiomeric purity dexanabinol for pharmaceutical copositions
08/31/2005EP1567241A2 Crystallization method and apparatus using an impinging plate assembly
08/31/2005EP1567203A2 Barriers for bioactive agent-containing polymeric coatings
08/31/2005EP1567198A2 Materials and methods for treating ocular-related disorders
08/31/2005EP1567193A1 Colon cleansing compositions
08/31/2005EP1567184A1 Phosphoprotein preparations for bioactive metal ion delivery and teeth remineralisation
08/31/2005EP1567174A2 Compositions for diabetes treatment and prophylaxis
1 ... 1759 1760 1761 1762 1763 1764 1765 1766 1767 1768 1769 1770 1771 1772 1773 1774 1775 1776 1777 1778 1779 ... 2991